Immutep 과거 순이익 실적

과거 기준 점검 0/6

Immutep 의 수입은 연평균 -18.3%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 22.3%의 비율로 증가했습니다. 매출은 연평균 15.7%의 비율로 감소해 왔습니다.

핵심 정보

-18.26%

순이익 성장률

4.86%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	-15.70%
자기자본이익률	-42.77%
순이익률	-1,218.02%
최근 순이익 업데이트	30 Jun 2025

최근 과거 실적 업데이트

업데이트 없음

Recent updates

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

매출 및 비용 세부 내역

Immutep가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGM:IMMP 매출, 비용 및 순이익 (AUD Millions)
날짜	매출	순이익	일반관리비
30 Jun 25	5	-61	9
31 Mar 25	5	-53	8
31 Dec 24	5	-44	8
30 Sep 24	4	-43	9
30 Jun 24	4	-43	9
31 Mar 24	4	-42	9
31 Dec 23	4	-41	9
30 Sep 23	4	-40	9
30 Jun 23	4	-40	9
31 Mar 23	4	-38	8
31 Dec 22	4	-37	7
30 Sep 22	5	-34	7
30 Jun 22	5	-32	7
31 Mar 22	4	-29	7
31 Dec 21	4	-26	7
30 Sep 21	4	-28	7
30 Jun 21	4	-30	6
31 Mar 21	5	-29	6
31 Dec 20	6	-27	6
30 Sep 20	10	-20	6
30 Jun 20	14	-13	6
31 Mar 20	13	-15	6
31 Dec 19	13	-16	6
30 Sep 19	9	-17	6
30 Jun 19	6	-18	6
31 Mar 19	5	-18	6
31 Dec 18	5	-17	7
30 Sep 18	6	-15	7
30 Jun 18	7	-13	7
31 Mar 18	6	-12	7
31 Dec 17	7	-10	6
30 Sep 17	5	-9	5
30 Jun 17	4	-9	4
31 Mar 17	3	-10	5
31 Dec 16	2	-10	5
30 Sep 16	2	-36	30
30 Jun 16	2	-62	54
31 Mar 16	2	-71	54
31 Dec 15	1	-82	54
30 Sep 15	1	-57	30
30 Jun 15	1	-32	6
31 Mar 15	1	-23	5

양질의 수익: IMMP 은(는) 현재 수익성이 없습니다.

이익 마진 증가: IMMP는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: IMMP은 수익성이 없으며 지난 5년 동안 손실이 연평균 18.3% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 IMMP의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: IMMP은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(59.1%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: IMMP는 현재 수익성이 없으므로 자본 수익률이 음수(-42.77%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/02/19 14:38
종가	2026/02/19 00:00
수익	2025/06/30
연간 수익	2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 우리의 Github 페이지에서 확인하실 수 있으며, 보고서를 활용하는 방법에 대한 가이드와 유튜브 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Immutep Limited는 16명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Colleen Kusy	Baird
Joel Beatty	Baird
Melissa Benson	Barrenjoey Markets Pty Limited

Immutep 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

Recent updates

Immutep Limited Achieves 50% Enrolment in Global TACTI-004 (KeyNOTE-F91) Phase III Trial in 1L NSCLC

Immutep Limited Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues At Robust Pace

Immutep Limited to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

Immutep Limited Announces Positive Data from the EFTISARC-NEO Trial

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented At ESMO Congress 2025

Immutep Limited, Annual General Meeting, Nov 27, 2025

Immutep Limited Announces Successful Completion of FDA Project Optimus Requirements

Immutep Limited Announces Update for Tacti-004 (Keynote-F91) Phase Iii Trial in First Line Non-Small Cell Lung Cancer

Immutep Limited Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation At CTOS 2025

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS

Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep Limited Announces Positive Update from Phase I Study of IMP761, A First-In-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Immutep Limited's Efti with Radiotherapy & KEYTRUDA®? (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue Sarcoma

Immutep Limited's Efti with Keytruda (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Immutep Limited: Surging On Positive Head And Neck Data

Immutep Limited's Efti in Combination with KEYTRUDA®? (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS

Immutep Limited Announces First Patient Dosed in TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster At the European Lung Cancer Congress 2025

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Limited Announces Patient Enrolment Complete in the Investigator-Initiated EFTISARC-NEO Trial

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024

Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Immutep secures €1.8M cash in French government's research tax credit

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep Limited Reports Positive Final Data from Insight-004 Trial

Immutep Limited Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

Immutep Limited Provides an Update on its Clinical and Preclinical Programs

Immutep Limited Enters Second Collaboration with Merck & Co., Inc. for New Randomised Phase IIB Trial in Head and Neck Cancer

Immutep Limited Expands Part B of TACTI-002 Collaboration Trial

Immutep Limited Announces Advancement of Phase II Trial for Eftilagimod Alpha in COVID-19 Patients to Randomised Portion of the Study

매출 및 비용 세부 내역

순이익 및 매출 추이